Troy D'amour, DO
Family Medicine · Joplin, MONPI 1376589804
Payments from drug & device makers
Across 674 payments — averaging $11.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Lilly USA, LLC$808
- Boehringer Ingelheim$796
- AbbVie$748
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$575
- plus $3K from 23 others
What the payments were for
- Food & beverage$8,001100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $1,297 |
| Novo Nordisk | 115 | $1,165 |
| Lilly USA, LLC | 70 | $808 |
| Boehringer Ingelheim | 70 | $796 |
| AbbVie(2 entities) | 106 | $748 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 61 | $575 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $358 |
| Pfizer | 32 | $358 |
| GSK | 30 | $347 |
| Johnson & Johnson | 21 | $267 |
| Amgen(2 entities) | 20 | $251 |
| Merck | 13 | $214 |
| Amarin Pharma, Inc. | 26 | $199 |
| Sunovion Pharmaceuticals Inc. | 9 | $110 |
| Axsome Therapeutics, Inc. | 4 | $70 |
| Novartis | 4 | $65 |
| Mylan Specialty L.p. | 4 | $55 |
| Bayer | 4 | $54 |
| Genentech USA, Inc. | 3 | $51 |
| Esperion Therapeutics, Inc. | 4 | $50 |
| Zyla Life Sciences, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Eisai Inc. | 2 | $25 |
| Ironwood Pharmaceuticals, Inc | 2 | $24 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Astellas Pharma US Inc | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$847
- BREZTRI$556
- SYMBICORT$291
- FASENRA$197
- BREZTRI AEROSPHERE$106
How this compares
$8,013 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $85,006 |
| JardianceEmpagliflozin | 97 | $71,388 |
| EliquisApixaban | 94 | $68,555 |
| MounjaroTirzepatide | 65 | $66,197 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $29,158 |
| XareltoRivaroxaban | 38 | $28,441 |
| FarxigaDapagliflozin Propanediol | 26 | $28,221 |
| JanuviaSitagliptin Phosphate | 33 | $20,914 |
| LinzessLinaclotide | 22 | $16,988 |
| Spiriva RespimatTiotropium Bromide | 18 | $15,369 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $15,304 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $14,743 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $12,449 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,964 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $796 | $116,804166 claims |
| Novo NordiskOzempic | $1,165 | $85,00671 claims |
| PfizerEliquis | $358 | $68,55594 claims |
| Lilly USA, LLCMounjaro | $808 | $66,19765 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $347 | $57,82293 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,297 | $38,18540 claims |
| Johnson & JohnsonXarelto | $267 | $28,44138 claims |
| MerckJanuvia, Janumet Xr | $214 | $27,67745 claims |
| AbbVieLinzess | $748 | $16,98822 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $9,24915 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $1 | $5,74112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Joplin
- Luke WickeJoplin$18K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.